Nuzenio

Alterity Therapeutics Releases

Alterity Therapeutics Releases news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 2 publisher sources 100/100 entity strength

Latest news

[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - Stock TitanStock Titan · Mon, 10 Aug 2026 10:04:46 GMT Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:40:29 GMT Alterity CEO Set to Present at Canaccord Growth Conference - Stock TitanStock Titan · Thu, 06 Aug 2026 11:25:00 GMT Alterity Therapeutics (NASDAQ: ATHE) plans Canaccord Growth Conference talk - Stock TitanStock Titan · Thu, 06 Aug 2026 10:06:42 GMT Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 11:41:44 GMT Alterity Therapeutics (NASDAQ: ATHE) outlines FDA-backed Phase 3 plan for ATH434 - Stock TitanStock Titan · Thu, 30 Jul 2026 10:05:21 GMT Alterity’s ATH434 Trial for Rare MSA May Enroll 200 Patients - Stock TitanStock Titan · Thu, 30 Jul 2026 07:00:00 GMT Alterity Therapeutics (NASDAQ: ATHE) sets August 31, 2026 expiry for 18.4M ATHO options - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Mon, 10 Aug 2026 10:04:46 GMT[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - Stock Titan

Thu, 06 Aug 2026 11:40:29 GMTAlterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference - The Manila Times

Thu, 06 Aug 2026 11:25:00 GMTAlterity CEO Set to Present at Canaccord Growth Conference - Stock Titan

Thu, 06 Aug 2026 10:06:42 GMTAlterity Therapeutics (NASDAQ: ATHE) plans Canaccord Growth Conference talk - Stock Titan

Thu, 30 Jul 2026 11:41:44 GMTAlterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update - The Manila Times

Thu, 30 Jul 2026 10:05:21 GMTAlterity Therapeutics (NASDAQ: ATHE) outlines FDA-backed Phase 3 plan for ATH434 - Stock Titan

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

NASDAQ6 live mentions ATHE6 live mentions Stock Titan Stock5 live mentions Titan5 live mentions Alterity Therapeutics5 live mentions Stock Titan Alterity5 live mentions Present4 live mentions Canaccord Growth Conference4 live mentions Therapeutics3 live mentions ALTERITY THERAPEUTICS LTD2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Alterity Therapeutics Releases.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.